MTAP deficiency has been reported for several tumor entities, with high frequency in mesothelioma, T cell acute lymphoblastic leukemia (T-ALL), gliomas, metastatic melanoma, and non-small cell lung cancer (NSCLC) (28). Here, MTAP is linked to mesothelioma.